Seabrook Partner, Cepheid at Front Line of Covid19 Battle

From medicaldevice-network.com: Cepheid has received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its rapid molecular diagnostic test, Xpert Xpress SARS-CoV-2.

The test is designed for the qualitative detection of SARS-CoV-2 virus, which causes coronavirus (Covid-19) disease. Designed to operate on the company’s automated GeneXpert Systems, it has a detection time of approximately 45 minutes.

Well done, Cepheid! As seen in this video, Seabrook Technology Group is a proud partner of Cepheid, and has helped to implement paperless manufacturing, increase production efficiency, and solidify regulatory compliance.